$CELG, sold for $74 billion, leaves a legacy of chutzpah in science and drug pricing pens the definitive Celgene obit. This is a compelling read, starting with a cabbie's stock tip.
Have to love Geoff Porges’ fearlessness to provide a real opinion. And great ⁦⁩ tale as always. $CELG
The biotechnology company Celgene, sold for $74 billion, leaves behind a legacy of chutzpah both in science and in how it priced its drugs.
Best M&A transaction was being "acquired" by . Great writer & article. Celgene, sold for $74 billion, leaves a legacy of chutzpah in science and drug pricing
History of the rise of until the recent purchase. Described by in
#Celgene, sold for $74 billion, leaves a legacy of chutzpah in science and #drugpricing via And yet, exemplary of my distaste for #healthcare capitalism, more generally. #biotech #pharma
OK. I have my second cup of tea and I am ready to start social media-ing for real. For all the people who were asking me if I was going to be doing long narratives at , there are 2,000 words on $CELG up for you. More in a few.
Well, "chutzpah" is one way to describe it. "Venal" is another good word that the reporter uses. Celgene, sold for $74 billion, leaves a legacy of chutzpah in science and drug pricing via
Celgene, sold for $74B, leaves legacy of chutzpah in science & drug pricing. Asks : 'Want to know why an industry that views itself as lifesaving and heroic is viewed by much of the public as price gouging and venal? Look here': via
Celgene, sold for $74 billion, leaves a legacy of chutzpah in science and drug pricing via
Others have been recommending it as well, and they're right - this is an excellent piece on Celgne
What was Celgene's legacy? Chutzpah. In science, business, and pricing. I spent a lot of time going through the company's history. Have a read.
Want to know how it is that people in the drug industry feel they are doing good, but outsiders see something more negative? Look at $CELG, which is being bough by $BMY for $74 billion. v
Reminder: if you want to be able to read STATPlus articles, you can use the code Herper19 for a discount on a full-year subscription. If not, hey, you can read my Celgene article if you haven't yet
‘Want to know why an industry that views itself as lifesaving and heroic is viewed by much of the public as price gouging and venal? Look here.’
Celgene, sold for $74 billion, leaves a legacy of chutzpah in science and drug pricing via
Celgene, sold for $74 billion, leaves a legacy of chutzpah in science and drug pricing via
Celgene, sold for $74 billion, leaves a legacy of chutzpah in science and drug pricing via
Celgene, sold for $74 billion, leaves a legacy of chutzpah in science and drug pricing via
Matt Herper on why Celgene (disappearing into Bristol) wasn’t a scientific innovator like Genentech, but did excel at drug pricing. via
Here's my goodbye to $CELG story from January. Looking forward to covering the new $BMY.